Nektar Therapeutics

NKTR Mid Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$76.99

+1.69% today

52W: $6.45 – $78.81

52W Low: $6.45 Position: 97.5% 52W High: $78.81

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

39.99x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$2.2B

Market Capitalization

Revenue Growth

-25.3%

YoY Revenue Growth

Profit Margin

-297.07%

Net profit margin

ROE

-217.94%

Return on Equity

Beta

1.18

Market sensitivity

Short Interest

12.96%

% of float sold short

Avg. Volume

1,125,772

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

Strong Buy

8 analysts

Avg. Price Target

$128.12

+66.42% upside

Target Range

$70.00 – $165.00

About the Company

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. It develops rezpegaldesleukin, which is in Phase 2b to treat underlying immune system imbalance in people with autoimmune disorders and inflammatory diseases; NKTR-0165 to treat ulcerative colitis, vitiligo, and multiple sclerosis; NKTR-0166 to treat autoimmune disease; NKTR-422 to treat fibrotic diseases; and NKTR-255 to treat solid tumors and large b-cell lymphoma. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; and Merck KGaA. The company was incorpo

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 63 Exchange: NCM